- Home
- AX vs PTGX Comparison
AX vs PTGX Comparison
Compare AX & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AX | PTGX |
|---|---|---|
| Founded | 1999 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 5.2B |
| IPO Year | 2004 | 2016 |
Fundamental Metrics
Financial Performance| Metric | AX | PTGX |
|---|---|---|
| Price | $93.76 | $103.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 13 |
| Target Price | $103.14 | ★ $107.38 |
| AVG Volume (30 Days) | 360.5K | ★ 824.8K |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 4.17 | N/A |
| Revenue | ★ $65,789,000.00 | N/A |
| Revenue This Year | $24.76 | $873.97 |
| Revenue Next Year | $10.86 | N/A |
| P/E Ratio | $22.41 | ★ N/A |
| Revenue Growth | ★ 1.78 | N/A |
| 52 Week Low | $55.50 | $41.10 |
| 52 Week High | $101.92 | $107.84 |
Technical Indicators
Market Signals| Indicator | AX | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 66.82 | 59.55 |
| Support Level | $92.78 | $76.63 |
| Resistance Level | $93.84 | $107.84 |
| Average True Range (ATR) | 2.17 | 4.14 |
| MACD | 1.40 | -0.28 |
| Stochastic Oscillator | 87.48 | 56.55 |
Price Performance
Historical ComparisonAbout AX Axos Financial Inc.
Axos Financial Inc is a bank holding company that operates through its bank subsidiary, BofI Federal Bank, a nationwide bank that provides financing for single and multifamily residential properties, small to medium-size businesses in certain sectors, and selected specialty finance receivables. Its operating segments are banking business segment and securities business segment. The bank distributed its products through a wide range of retail distribution channels, including only banking brands, affinity groups, and sales teams, among others. The majority of the bank's mortgage exposure is titled toward the state of California, particularly its southern region. Net interest income is a majority of the bank's revenue.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.